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Investigators Toronto, Ontario, Canada; and Riyadh, Saudi Arabia
Background: Current evidence suggests that statin use plays an important role in improving adverse cardiovascular
outcomes in patients with atherosclerosis. However, limited population-based data are available on use of statin therapy
in these patients in Canada. We sought to study trends in statin use to treat these patients in Ontario during a 10-year
period.
Methods: We conducted a population-based cross-sectional time series analysis between April 1, 1995, and March 31,
2004, using health care data from Ontario, Canada.
Results:During the study period, 343,154 elderly patients with atherosclerosis were identified. Of these, 235,615 (68.7%)
had coronary artery diseases (CAD), 115,012 (33.5%) had cerebrovascular disease (CVD), and 23,886 (7.0%) had
peripheral arterial disease (PAD). About 46% were women, and mean patient age was 77.1 (SD, 7.5) years. During the
study period, the percentage of patients treated with a statin in each group increased considerably, from 9.8% to 55.3%
in all atherosclerotic patients (P < .01), from 11.8% to 61.2% in CAD patients (P < .01), from 5.3% to 41.2% in CVD
patients (P< .01), and from 6.8% to 43.3% in PAD patients (P< .01). During the entire study period, the percentage of
statin users was lowest among PAD and CVD patients, followed by patients with both a history of PAD and CVD.
Conclusion: The use of statin therapy in elderly patients with symptomatic atherosclerosis has increased substantially
during the past decade, but many patients remain untreated. The suboptimal use is greatest among patients with PAD or
CVD, or both, and lowest in patients with CAD. Given the heightened risk of cardiovascular adverse outcomes in patients
with atherosclerosis, these data have important and immediate implications. ( J Vasc Surg 2008;48:607-12.)Atherosclerosis is the leading cause of death in adults
worldwide.1 The reduction of the adverse cardiovascular
outcomes associated with atherosclerosis through risk fac-
tor identification and modification has been an active area
of research in recent decades. Among these modifiable risk
factors is cholesterol, which plays an important role in the
development and progression of atherosclerotic disease.
Modifying the lipid profile is an important risk reduction
strategy in improving the adverse outcomes associated with
atherosclerotic disease.
Several large randomized controlled trials have demon-
strated the efficacy of 3-hydroxy-3-methylglutaryl coenzyme
A inhibitors (statins) in the primary and secondary prevention
of cardiovascular adverse events.2-12 In addition, it has been
shown that statins have an anti-inflammatory effect that im-
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doi:10.1016/j.jvs.2008.04.057proves clinical outcomes independent of the reduction in
cholesterol levels.13,14 This compelling evidence has led sev-
eral expert committees to publish evidence-based practice
guidelines recommending the use of statins in patients with
atherosclerosis.15-20
Despite the publication of many practice guidelines advo-
cating the use of statins in patients with atherosclerosis, a care
gap has been documented in several studies showing under-
utilization of statin therapy in this population.21-30 However,
most of the available studies offer a limited understanding of
statin prescription with regards to the clinical presentation of
atherosclerotic disease, including coronary artery disease
(CAD) vs cerebrovascular disease (CVD) vs peripheral arterial
disease (PAD). Information published thus far from the Re-
duction of Atherothrombosis for Continued Health
(REACH) Registry has demonstrated suboptimal use of st-
atins according to atherosclerotic clinical presentation but
contains no indication on the trends of statin usage.21 Fur-
thermore, patients were recruited by their own physicians in
this study, suggesting that the true degree of undertreatment
in general clinical practice might be underestimated. The aim
of this study was to examine trends in statin use among
subjects with atherosclerotic disease in Ontario, Canada.
METHODS
We conducted a population-based cross-sectional time
series analysis using the linked administrative health care
databases of Ontario, Canada. Ontario has a population of
about 12 million, of whom approximately 1.5 million are
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universal access to hospital care, physicians’ services, and
prescription drug coverage. This study was approved by the
Ethics Review Board of Sunnybrook Health Sciences Cen-
tre, Toronto, Ontario, Canada.
The study time frame was divided into 36 intervals of 3
months (quarters) from April 1, 1995, to March 31, 2004.
Eligible subjects were Ontario residents, aged 65 years,
who had a history of CAD, CVD, or PAD in the 3-year
period before the beginning of each quarter. We used the
Canadian Institutes of Health Information discharge ab-
stract database (CIHI-DAD) for the province of Ontario
and the Ontario Health Insurance Plan (OHIP) database
to identify patients with CAD, CVD, or PAD. CIHI-DAD
captures diagnoses and procedures of patients admitted to
hospitals, and OHIP captures physicians’ billing claims for
services provided to residents of the Province of Ontario.
We defined CAD, CVD, and PAD using a combination of
the most responsible diagnosis, a procedure captured in the
hospital database, or a physician billing claim for translumi-
nal angiography captured in the OHIP database. Appendix
1 (online only) describes the algorithms used to identify
patients with atherosclerosis by clinical presentation. We
used the Ontario Drug Benefit Plan (ODB) Database to
capture statin use. The ODB contains information on
prescription drugs dispensed to elderly residents and indi-
viduals receiving social assistance.
In each quarter we assessed the percentage of living
patients with CAD, CVD, and PAD treated with a statin by
dividing the number of patients that had been dispensed a
statin in that quarter by the total number of patients alive at
the beginning of that interval. We examined whether pa-
tients had a history of hypertension, hyperlipidemia, diabe-
tes mellitus, heart failure, or renal failure by analyzing their
hospitalization and outpatient records in the administrative
databases. We also used the Charlson Comorbidity Index
score to record their overall level of comorbidity.31
Table. Characteristics of atherosclerotic patients and perce
Variable
No. (%); mean  SD All
Number 85,099
Age 75.3  7.0 7
Female 40,258 (47.3) 25
CAD 55,866 (65.6) 55
CVD 26,556 (31.2) 2
PAD 6077 (7.1)
Hypertension 30,178 (35.5) 18
DM 21,873 (25.7) 13
CHF 16,576 (19.5) 13
CRF 2211 (2.6) 1
Hyperlipidemia 3849 (4.5) 3
Charlson Index
0 14,284 (16.8) 13
1 31,830 (37.4) 18
2 38,985 (45.8) 23
Statin 8088 (9.5) 6CAD, Coronary artery disease; CHF, congestive heart failure; CVD, cerebrovascuIn a secondary analysis, we further stratified the patients
with atherosclerosis into seven subgroups according to the
type of atherosclerotic disease and the risk of experiencing a
cardiovascular event: patients with only one of the condi-
tions present (PAD, CAD, or CVD), patients with two of
the conditions (CAD and CVD; CAD and PAD, or PAD
and CVD), and patients with all three conditions (CAD,
CVD, and PAD). Fig 1 shows the distribution of patients
based on the clinical presentation of atherosclerosis disease.
Patients who presented with only one of the three condi-
tions were considered to be at low risk of experiencing a
e using statins at three points in time
April 1995
D CVD PAD
66 26,556 6077
6.8 77.1  7.2 74.6  6.8
(45.6) 13,802 (52.0) 2481 (40.8)
(100.0) 2291 (8.6) 746 (12.3)
(4.1) 26,556 (100.0) 413 (6.8)
(1.3) 413 (1.6) 6077 (100.0)
(33.0) 11,386 (42.9) 2206 (36.3)
(24.8) 6723 (25.3) 2560 (42.1)
(24.1) 3173 (11.9) 1059 (17.4)
(2.9) 514 (1.9) 256 (4.2)
(5.8) 661 (2.5) 156 (2.6)
(24.2) 6 (0.0) 775 (12.8)
(33.3) 12,142 (45.7) 1624 (26.7)
(42.5) 14,411 (54.3) 3678 (60.5)
(11.8) 1396 (5.3) 414 (6.8)
Fig 1. Distribution of patients by symptoms according to their
atherosclerotic disease clinical presentation.CAD,Coronary artery
disease; CVD, cerebrovascular disease; PAD, peripheral arterial
disease.ntag
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moderate risk, and patients with all three conditions were
considered to be at high risk of experiencing a cardiovascu-
lar event. We further assessed the statin use over time
among these groups.
We used time series analysis32 involving autoregressive
integrated moving average models and exponential
smoothing models to evaluate changes of statin use over
time. Stationarity was assessed using the autocorrelation
function and the augmented Dickey-Fuller test.33 The
autocorrelation, partial autocorrelation, and inverse auto-
correlation functions were assessed for model parameter
appropriateness and seasonality. The presence of white
noise was assessed by examining the auto correlations at
various lags using the Ljung-Box 2 statistic.34 Analyses
were conducted with the use of SAS 9.1 software (SAS
Institute, Cary, NC).
RESULTS
Between April 1, 1995, and January 1, 2004, 343,154
atherosclerotic patients were examined; of these, 235,615
(68.66%) had CAD, 115,012 (33.52%) had CVD, and
23,886 (6.96%) had PAD. Fig 1 depicts the overall distri-
bution of patients with atherosclerosis according to the
clinical presentation of atherosclerotic disease. About 46%
were women, and the mean patient age was 77.1 (SD, 7.5)
years.
The Table describes the characteristics of patients and
their statin use at three points in time: during the first
quarter of analysis (April to June 1995), 5 years later (April
to June 2000), and in the last quarter of analysis (January to
March 2004). In April 1995, there were 85,099 atheroscle-
rotic patients, of whom about 66% had CAD, 31% had
CVD, and 7% had PAD. The number of atherosclerotic
patients 5 years later was 93,670, and 5 years thereafter,
93,244. The proportion with CAD, CVD, and PAD at each
interval remained relatively constant.
Table. Continued.
April 2000
All CAD CVD PAD
93,670 64,769 27,169 5,447
75.7  7.0 75.0  6.8 77.4  7.3 75.0  6.6
43,657 (46.6) 28,942 (44.7) 14,110 (51.9) 2182 (40.1)
64,769 (69.1) 64,769 (100.0) 2588 (9.5) 774 (14.2)
27,169 (29.0) 2588 (4.0) 27,169 (100.0) 430 (7.9)
5447 (5.8) 774 (1.2) 430 (1.6) 5447 (100.0
40,844 (43.6) 27,202 (42.0) 13,366 (49.2) 2529 (46.4)
29,323 (31.3) 19,955 (30.8) 8394 (30.9) 2666 (48.9)
19,495 (20.8) 16,405 (25.3) 3341 (12.3) 1126 (20.7)
3769 (4.0) 2917 (4.5) 809 (3.0) 417 (7.7)
15,456 (16.5) 13,443 (20.8) 2320 (8.5) 498 (9.1)
15,786 (16.9) 15,086 (23.3) 6 (0.0) 733 (13.5)
32,918 (35.1) 20,540 (31.7) 11,556 (42.5) 1289 (23.7)
44,966 (48.0) 29,143 (45.0) 15,611 (57.5) 3425 (62.9)
33,898 (36.2) 27,882 (43.0) 6032 (22.2) 1323 (24.3)Overall, the PAD patient group had the highest level of
comorbidity, followed by CVD patients, as determined by
the proportion of patients with a Charlson comorbidity
score of 2. PAD patients were more likely to have a
history of diabetes and chronic renal failure, CAD patients
were more likely to have a history of congestive heart failure
and hyperlipidemia, and CVD patients were older and
more likely to have a history of hypertension. During the
study period, the percentage of statin users increased con-
siderably in all groups of atherosclerotic patients, increasing
fourfold (11.8% to 61.2%) in CAD patients, sevenfold
(5.3% to 41.2%) in CVD patients, and fivefold (6.8% to
43.3%) in PAD patients.
Fig 2 depicts temporal trends in the percentage of statin
users among atherosclerotic patients during the study pe-
riod. Satin usage increased significantly across all groups of
January 2004
ALL CAD CVD PAD
93,244 66,407 25,582 4,219
76.4  7.2 75.8  7.1 78.3  7.4 75.7  6.8
,113 (45.2) 28,361 (42.7) 13,294 (52.0) 1715 (40.6)
,407 (71.2) 66,407 (100.0) 2117 (8.3) 565 (13.4)
,582 (27.4) 2117 (3.2) 25,582 (100.0) 322 (7.6)
4219 (4.5) 565 (0.9) 322 (1.3) 4219 (100.0)
,157 (50.6) 33,070 (49.8) 13,948 (54.5) 2226 (52.8)
,106 (34.4) 23,094 (34.8) 8470 (33.1) 1930 (45.7)
,959 (20.3) 16,350 (24.6) 2834 (11.1) 795 (18.8)
6605 (7.1) 5233 (7.9) 1337 (5.2) 506 (12.0)
,857 (12.7) 10,348 (15.6) 1698 (6.6) 333 (7.9)
,355 (16.5) 15,115 (22.8) 6 (0.0) 253 (6.0)
,514 (34.9) 20,989 (31.6) 10,633 (41.6) 1231 (29.2)
,375 (48.7) 30,303 (45.6) 14,947 (58.4) 2735 (64.8)
,255 (54.9) 40,613 (61.2) 10,537 (41.2) 1825 (43.3)
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September 2008610 Al-Omran et alpatients with atherosclerosis (P  .01 for each group). In
the last quarter of analysis (quarter starting in January
2004), the percentage of statin users among patients with
CVD or patients with PAD was 50%.
Fig 3 displays the percentage of statin users over time in
atherosclerotic patients according to their risk of experienc-
ing a cardiovascular outcome. Statin usage increased signif-
icantly over time in all low-risk (Fig 3,A) andmoderate-risk
patients (Fig 3, B; P  .01 for each risk group). However,
patients with CAD had the highest rates of statin usage
relative to the CVD and PAD patients, who had higher
overall comorbidity profiles. In the last quarter of analysis,
the percentage of statin users in the low-risk group of CAD
patients was about 20% higher than in the low-risk group of
PAD or CVD patients (Fig 3, A). In the moderate-risk
subgroup, the percentage of statin use in patients with both
a history of CVD and PAD was lowest throughout the
entire study period and was 50% in the last quarter of
analysis (Fig 3, B). The difference between statin users was
significantly higher among moderate-risk patients with a
history of CVD and PAD compared with low-risk patients
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Fig 3. A, Temporal trend in the percentage of users of statins
among the low-risk subgroup of atherosclerotic patients, defined
as the presence of only one atherosclerotic clinical condition,
defined as coronary artery disease (CAD, diamonds), cerebrovas-
cular disease (CVD, triangle), and peripheral arterial disease
(PAD, crosses). B, Temporal trend in the percentage of users of
statins among the subgroups of atherosclerotic patients with two
atherosclerotic conditions, consisting of CAD and CVD (dia-
monds), CAD and PAD (triangles), and CVD and PAD (crosses).with PAD (P  .001).DISCUSSION
In this study we have shown that despite the significant
increase in the use of statin therapy among patients with
atherosclerosis from 1995 to 2004, usage remains subop-
timal. There is strong evidence supporting the use of statins
therapy in patients with atherosclerosis, and our results
indicate that there is a care gap in the management of
atherosclerosis patients in Ontario, Canada.
The introduction of statin therapy to clinical practice
has resulted in a major revolution in the management of
atherosclerosis. A recent meta-analysis of 14 randomized
trials of statins, which included data from 90,056
participants, showed that for each 1.0-mmol/L reduc-
tion in low-density lipoprotein (LDL) cholesterol, there
was also reduction of about 12% in all-cause mortality, a
23% reduction in the risk of myocardial infarction or
coronary-related mortality, a 24% reduction in the need
for coronary revascularization, and a 17% reduction in
the rate of fatal or nonfatal stroke.2 Moreover, two
recent randomized clinical trials have shown that reduc-
ing the inflammatory component of cardiovascular
disease—one of the pleiotropic effects of statins—
improves clinical outcomes and that this effect is inde-
pendent of the reduction in cholesterol levels.13,14
Compelling evidence from the literature has led sev-
eral expert panels to recommend the use of statins in all
patients with atherosclerosis to lower their LDL choles-
terol level100 mg/dL.15,17 A more recent recommen-
dation is to achieve LDL cholesterol level 70 mg/dL
for higher-risk atherosclerotic patients.16,18 With the
increasing recognition of the disease burden of PAD,
separate guidelines have been published to encourage
the use of risk reduction therapies, including statins
therapy, in patients with PAD.35
Our findings raise several issues. The underuse of st-
atins was more prominent among low-risk patients with
PAD or with CVD and among moderate-risk patients with
CVD and PAD compared with patients with CAD. In
general, however, patients with PAD were more likely to
have a history of diabetes and chronic renal failure andmore
likely to be sicker. Furthermore, the percentage of athero-
sclerotic patients using statins was highest among those
with a history of CAD, with or without PAD or CVD.
Suboptimal use of statin therapy has been reported in
many other Western countries.22-29 Ma et al,22 in a
population-based study from the United States, showed
that only 19% of patients eligible for lipid-lowering drugs
were actually being treated. The authors also found that
the rate of statin use increased from 9% to 49% between
1992 and 2000, and then declined to 36% in 2002.22 In
another population-based study conducted in the
United Kingdom, only 56.3% of men and 41.1% of
women with CAD were using statins.26 Furthermore,
results from the REACH registry, which collected data
on patients with atherosclerosis from 44 countries, indi-
cated that 76.2% of patients with CAD were taking
JOURNAL OF VASCULAR SURGERY
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CVD and PAD, respectively.21
Our study adds support to the available literature
documenting inequities in the use of risk reduction
therapies for patients with PAD compared with patients
with CAD.36 Furthermore, these data can be useful in
supporting a call for action for PAD management and
public awareness.36
There are several possible explanations for our findings:
● There might be a gap in physicians’ knowledge and
consequent lack of action in managing risk factors in
patients with atherosclerosis, in particular patients with
a history of PAD.37-39
● Physicians tend to treat elderly patients less aggres-
sively than younger patients (age bias), which could
explain why only about half of our study population
was being treated with statins.25,26
● Physicians might have decided not to prescribe statins
if patients had normal cholesterol levels.
● Patients with high cholesterol levels were prescribed
other lipid-lowering medications or managed with
nonpharmacologic agents such as diet control, weight
loss, or naturopathic remedies.
Our study has several strengths that should be noted. It
is a population-based study, and therefore, the results are
generalizable to residents of Ontario aged 65 and to
elderly patients in communities with similar access to health
care. In addition, our study is absent of reporting bias due
to the nature of the administrative data used.
Certain limitations related to the use of administrative
databases for research purposes merit emphasis. The accu-
racy of coding for many diagnoses and procedures is uncer-
tain. Although high accuracy for coding demographic,
primary diagnosis, and procedural data in the Canadian
Institute for Health Information (CIHI) hospital discharge
abstract database has been shown previously; the accuracy
for coding comorbidities is low.40,41 These potential inac-
curacies may have impacted the magnitude of the reported
comorbidities in our patient population. In addition, we
have no direct measure of drug adherence, but given that in
Ontario there is a pharmacy-dispensing fee, even for resi-
dents with full drug coverage, it is reasonable to assume
that a drug that is purchased will be taken by the patient.
The administrative databases do not capture nonpre-
scription drugs or nonpharmacologic treatments, making it
impossible to assess whether alternative treatments were
being used to manage the cholesterol of patients who were
not taking statins. In addition, the results of cholesterol
levels or any reported adverse effect or contraindications of
statin therapy are also not captured in these databases.
Statin use may be overestimated in this study because
the patients included were only those with enough symp-
toms to be admitted to hospitals. It is therefore possible
that the true care gap be even higher than what we found.
Finally, we were only able to study elderly patients, because
in Ontario, full drug coverage is only granted to residents
aged 65 and individuals receiving social assistance.CONCLUSION
Weobserved a considerable increase in the use of statins
in elderly patients with symptomatic atherosclerosis during
a 10-year period; however, the use of statins in this patient
population was still suboptimal. This care gap was more
prominent among patients with PAD or CVD, or both,
than among patients with CAD. Given the heightened risk
of cardiovascular adverse outcomes in patients with athero-
sclerosis, these data have important and immediate impli-
cations. If the current practice continues, the observed
treatment gaps are expected to persist for patients with
PAD or CVD, or both, and to lesser extent for patients with
CAD. These findings may be useful for guiding targeted
interventions such as self-audit of practice, focused con-
tinuing medical education programs, the inclusion of risk
reduction pharmacotherapy as a plenary topic at scientific
meetings, and other educational outreach programs that
aim to bring physicians’ practice into agreement with cur-
rent guidelines for cardiovascular risk reduction.
The opinions, results, and conclusions are those of the
authors and no endorsement by the Ontario Ministry of
Health and Long-TermCare or by the Institute for Clinical
Evaluative Sciences is intended or should be inferred.
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● Coronary artery disease (CAD) patients—Hospitalization with a primary discharge diagnosis for CAD [myocardial
infarction, acute coronary syndrome or angina] or a procedure indicating coronary revascularization.
Most responsible diagnosis:
International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9): 410, 411, 412, 413, 414;
International Classification of Diseases, 10th Revision (ICD-10): I20, I21, I22, I23, I24, I25
Or procedure:
Canadian Classification of Procedures (CCP): 4811-4819; 4802, 4803, 4809
Canadian Classification of Health Interventions (CCI): 1IJ76, 1IJ80, 1IJ50, 1IJ57
● Cerebrovascular disease (CVD) patients—Hospitalization with a primary discharge diagnosis for CVD (ischemic stroke
or transient ischemic attacks) or a procedure code indicating carotid endarterectomy.
Most responsible diagnosis:
ICD-9: 434, 435, 436
ICD-10: I63, I64, I65, I66, G45
Or procedure:
CCP: 5012
CCI: 1JE57, 1JE87
● Peripheral arterial disease (PAD) patients—Hospitalization with a primary discharge diagnosis for PAD (atherosclerosis
of aorta or peripheral artery or gangrene) or a procedure code indicating peripheral arterial revascularization or
amputation for PAD indication.
Most responsible diagnosis:
ICD-9: 440.0, 440.2, 440.8, 440.9, 443.9, 447.1, 7854
ICD-10: I70.0, I70.2, I70.8, I70.9, I73.9, I77.1, R02
Or procedure:
CCP: 5125, 5129, 9611, 9612, 9613, 9614, 9615
CCI: 1KA76, 1JM76, 1KG76, 1VC93, 1VG93, 1VQ93, 1WA93, 1WJ93, WL93, 1WM93, 1KE76, 1KE76,
1KG50, 1KG80, 1KT76
Ontario health insurance plan (OHIP) fee code: J025
Identification of comorbidities
● Hypertension (ICD-9: 401-405; ICD-10: I10-I15)
● Hyperlipidemia (ICD-9: 2720, 2722, 2723, 2724, 2725, 2726, 2727; ICD-10: I78)
● Diabetes (ICD-9: 250; ICD-10: E10, E14)
● Heart Failure (ICD-9: 428; ICD-10: I50)
● Renal Failure (ICD-9: 585, 586; ICD-10: N17-N18)
